1. < Prostate Cancer
Profile picture for texan1961

Orgovyx and Cyberknife

Posted by texan1961 @texan1961, 6 days ago

Hello: I am 64. 3+4
/7. I am scheduled to begin Orgovyx 30 days before cyberknife. I saw mentioned that with an intermediate case, a 90 day orgovyx treatment is suggested. Is tbar correct? I am not sure if I understood my oncologist regarding length of orgovyx. I also am worried about the heart electricity issues orgovyx has...

Interested in more discussions like this? Go to the Prostate Cancer Support Group.

Profile picture for brianjarvis
brianjarvis | @brianjarvis | 6 days ago

Typically for a Gleason 7(3+4) (favorable intermediate), ADT is not standard (but can still be used). (See the attached NCCN guidelines for favorable intermediate risk prostate cancer.) (However, with a Gleason 7(4+3) (unfavorable intermediate), the NCCN guidelines recommend 4-6 months of ADT.)

> Do you have additional risk factors?

> With your 3+4, what is the % of “4”?

Actually, Orgovyx has the least risk of cardiovascular events of the ADTs they could’ve chosen. (The HERO study for Orgovyx showed significantly lower major adverse cardiovascular events with Orgovyx compared to leuprolides (Lupron, Eligard, etc.).

REPLY
3 replies
Profile picture for brianjarvis
brianjarvis | @brianjarvis | 6 days ago
In reply to @brianjarvis "Typically for a Gleason 7(3+4) (favorable intermediate), ADT is not standard (but can still be used)...." + (show)
Profile picture for brianjarvis @brianjarvis

Typically for a Gleason 7(3+4) (favorable intermediate), ADT is not standard (but can still be used). (See the attached NCCN guidelines for favorable intermediate risk prostate cancer.) (However, with a Gleason 7(4+3) (unfavorable intermediate), the NCCN guidelines recommend 4-6 months of ADT.)

> Do you have additional risk factors?

> With your 3+4, what is the % of “4”?

Actually, Orgovyx has the least risk of cardiovascular events of the ADTs they could’ve chosen. (The HERO study for Orgovyx showed significantly lower major adverse cardiovascular events with Orgovyx compared to leuprolides (Lupron, Eligard, etc.).

Jump to this post

@brianjarvis NCCN guidelines for favorable intermediate risk prostate cancer
REPLY
Profile picture for texan1961
texan1961 | @texan1961 | 6 days ago
In reply to @brianjarvis "Typically for a Gleason 7(3+4) (favorable intermediate), ADT is not standard (but can still be used)...." + (show)
Profile picture for brianjarvis @brianjarvis

Typically for a Gleason 7(3+4) (favorable intermediate), ADT is not standard (but can still be used). (See the attached NCCN guidelines for favorable intermediate risk prostate cancer.) (However, with a Gleason 7(4+3) (unfavorable intermediate), the NCCN guidelines recommend 4-6 months of ADT.)

> Do you have additional risk factors?

> With your 3+4, what is the % of “4”?

Actually, Orgovyx has the least risk of cardiovascular events of the ADTs they could’ve chosen. (The HERO study for Orgovyx showed significantly lower major adverse cardiovascular events with Orgovyx compared to leuprolides (Lupron, Eligard, etc.).

Jump to this post

Yes. Tonsil cancer survivor. They did an AI review of my biopsy:

At your consult appointment, we talked about running a test called Artera AI on your biopsy sample to help us determine if the hormone therapy would be beneficial to you. We have the results and it shows that the biopsy sample is positive for the ADT biomarker, meaning that you would benefit from the hormone blocking therapy.

Yahoo Mail: Search, Organize, Conquer

REPLY
Profile picture for texan1961
texan1961 | @texan1961 | 6 days ago
In reply to @brianjarvis "Typically for a Gleason 7(3+4) (favorable intermediate), ADT is not standard (but can still be used)...." + (show)
Profile picture for brianjarvis @brianjarvis

Typically for a Gleason 7(3+4) (favorable intermediate), ADT is not standard (but can still be used). (See the attached NCCN guidelines for favorable intermediate risk prostate cancer.) (However, with a Gleason 7(4+3) (unfavorable intermediate), the NCCN guidelines recommend 4-6 months of ADT.)

> Do you have additional risk factors?

> With your 3+4, what is the % of “4”?

Actually, Orgovyx has the least risk of cardiovascular events of the ADTs they could’ve chosen. (The HERO study for Orgovyx showed significantly lower major adverse cardiovascular events with Orgovyx compared to leuprolides (Lupron, Eligard, etc.).

Jump to this post

@brianjarvis

Here is the 7 biopsy result:
Prostate, right, core biopsy
Histologic Type: Acinar adenocarcinoma
Histologic Grade (Gleason Pattern)
Primary (Predominant) Pattern: Grade 3
Secondary (Worst Remaining) Pattern: Grade 4
Total Gleason Score: 7
Grade Group: 2

REPLY
Please sign in or register to post a reply.